Current Neuro-Oncology

Volume 28 Number 19
10 July 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 19, 10 July

Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M.
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Nat Cancer. 2026 Jul 1. doi: 10.1038/s43018-026-01199-y. PMID: 42387024. Trial registration ID: NCT02454634. ˍ

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E, Philips C, Kros JM, Bady P, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Jacob J, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Balana C, Azevedo ALS, Clement PM, Berghoff A, Tzuk-Shina T, Weller M, Nordal RA, Rees J, Lacombe DA, Mason WP, Stupp R.
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).
J Clin Oncol. 2026 Jul 2:JCO2502735. doi: 10.1200/JCO-25-02735. PMID: 42391581. Trial registration ID: EORTC 22033-26033˰ ˍ

Marciscano AE, Shih HA.
Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.
J Clin Oncol. 2026 Jul 2:JCO2600771. doi: 10.1200/JCO-26-00771. PMID: 42391595. ˍ

Lin J, Tang W, Li K, Chen Z, Zhang H, Ye Z, Li Z, Qu S, Huang G, Yi GZ.
Clinical, surgical, and molecular characteristics and outcomes of adult patients with diffuse midline glioma, H3 K27-altered, treated with surgical resection.
J Neurooncol. 2026 Jul 2;178(3):85. doi: 10.1007/s11060-026-05690-5. PMID: 42390632˰ ˍ

Linkowski L, Messing I, Berger M, Hollawell C, Friedes C, Alexander D, Wang X, Desai AS, Phillips RE, O'Rourke DM, Amankulor NM, Jackson C, Hubbeling H, Kurtz G, Bagley SJ, Bradley JD, Mohan S, Alonso-Basanta M, Lebow ES.
Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.
Int J Radiat Oncol Biol Phys. 2026 Jul 2:S0360-3016(26)03919-2. doi: 10.1016/j.ijrobp.2026.06.3058. PMID: 42392324. ˍ

Sharpe MA, Baskin AM, Teh BS, Butler EB, Baskin DS.
Optimizing the Stupp protocol for treatment of glioblastoma: eliminating age bias, enhancing treatment timing, use of stereotactically-guided sequential boost, and dexamethasone dosing.
J Neurooncol. 2026 Jul 3;178(3):88. doi: 10.1007/s11060-026-05685-2. PMID: 42397615. ˍ

Chen L, Li S, Wang L, Li H, Cai L, Lai M.
Fulminant extraneural metastases in MYC-amplified Group 3 medulloblastoma: a pediatric case report.
Childs Nerv Syst. 2026 Jul 4;42(1):284. doi: 10.1007/s00381-026-07351-4. PMID: 42399488. ˍ

Zhang Y, Chi X, Liu K, Ma Y, Zhang S, Ma X, Sun S, Zhang Y, Zhang K, Huang N, Cheng X, Ji N.
Personalized neoantigen-pulsed autologous dendritic cells in newly-diagnosed glioblastoma: a phase Ib trial.
Nat Commun. 2026 Jul 4. doi: 10.1038/s41467-026-75066-w. PMID: 42401550. Trial registration ID: NCT04968366. ˍ

Mathen P, Chaudhry H, Mackey M, Cooley-Zgela T, Masciocchi M, Li B, Huang E, Wu J, Smart D, Krauze A, Camphausen K.
Phase I dose escalation of the Exportin 1 inhibitor, Selinexor, in combination with chemoradiation in patients with newly diagnosed glioblastoma.
medRxiv [Preprint]. 2026 Jul 7:2026.06.25.26356263. doi: 10.64898/2026.06.25.26356263. PMID: 42465896. Trial registration ID: NCT04216329. ˍ

Murakami K, Kijima N, Kuroda H, Tachi T, Ikeda S, Nakagawa K, Wada Y, Hagioka T, Hatanaka N, Hirayama R, Kishima H, Hosen N.
Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.
Cancer Immunol Immunother. 2026 Jul 8. doi: 10.1007/s00262-026-04475-z. PMID: 42418010. ˍ

Nabors LB, Lobbous M, Han X, Fiveash J, Di Stasi A, Rochlin K, Oster R, Pillay T, Miller R, Chandrashekar DS, Ter Haak M, Ho W, Lamb LS Jr.
Intracranial Injection of Investigational Ex Vivo Expanded and Activated Gamma-Delta T Cells Engineered With a Methylguanine-DNA Methyltransferase-Expressing Lentivector in Patients With Primary Glioblastoma.
J Clin Oncol. 2026 Jul 8:JCO2502463. doi: 10.1200/JCO-25-02463. PMID: 42418736. Trial registration ID: NCT04165941˰ ˍ

Chen Y, Reynolds K, Koch MRA, Petrakian CF, Good Z, Yamada-Hunter S, Sotillo E, Song KW, Mahdi J, Majzner R, Desai MH, Huang YW, Daghagh H, Ehlinger ZJ, Iswari N, Sabatti C, Baggott C, Rietberg SP, Mo KC, Tsui KCY, Hamilton MP, Egeler E, Moon J, Erickson C, Jacobs A, Duh AK, Beebe B, Carr C, Fujimoto M, Kunicki M, Lim AS, Li A, Brown AK, Kuo A, Kaur A, Soundaranayagi SR, Prabhu S, Grant G, Prolo LM, Campen C, Partap S, Davis KL, Feldman SA, Tunuguntla R, Cochran JR, Sahaf B, Heitzeneder S, Monje M, Ramakrishna S, Mackall C.
Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.
medRxiv [Preprint]. 2026 Jul 9:2026.06.25.26356492. doi: 10.64898/2026.06.25.26356492. PMID: 42465905. Trial registration ID: NCT04196413. ˍ

Haresh KP, Thimmarayappa A, Roy S, Gupta S.
Timing of temozolomide in adult glioma: An exploratory study of an adaptive pre-radiotherapy approach in a mixed-grade cohort.
J Oncol Pharm Pract. 2026 Jul 9:10781552261451881. doi: 10.1177/10781552261451881. PMID: 42423607˰ ˍ

Kurihara H, Narita Y, Ito K, Sato H, Miyakita Y, Takahashi M, Ohno M, Yanagisawa S, Okita NT, Sadachi R, Machida R, Tateishi K, Yoshii Y, Waki A, Hashimoto H, Suzuki H, Zhang MR, Kawamura K, Honda N, Yoshimoto M, Matsumoto H.
First-in-human phase I study of hypoxia-targeting ⁶⁴Cu-ATSM radioligand therapy in patients with malignant brain tumors (STAR-64).
ESMO Open. 2026 Jul 10;11(8):108249. doi: 10.1016/j.esmoop.2026.108249. PMID: 42431136. Trial registration ID: jRCT2091220362. ˍ

Lim M, Ye X, Piotrowski AF, Desai A, Ahluwalia MS, Walbert T, Lesser G, Ellingson BM, Peereboom DM, Fisher JD, Desideri S, Jackson C, Pant A, Jain A, Verma R, Oberlton B, Piyadasa H, Bettegowda C, Engle L, Taube J, Bendall SC, Choi J, Drappatz J, Lieberman FS, Kleinberg LR, Pardoll DM, Nabors LB, Wen PY, Grossman SA.
Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.
Nat Med. 2026 Jul 10;32(7):2449-2460. doi: 10.1038/s41591-026-04475-7. PMID: 42432293. Trial registration ID: NCT02658981. ˍ

Paul G, Bjartmarz H, Kirkeby A, Nelander J, Smith R, Kayhanian S, Evans A, Harry B, Cutting E, Fazal S, Lao-Kaim NP, van Vliet T, Ullén S, Grubor I, Hansson O, Piccini P, Lindvall O, Björklund A, Widner H, Parmar M, Barker RA.
Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.
Nat Med. 2026 Jul 9. doi: 10.1038/s41591-026-04525-0. PMID: 42426223. Trial registration ID: NCT05635409. ˍ News